Table 2

 Angiographic parameters for studies with sirolimus eluting stents

StudyIndications for PCIMean RVD (mm)Mean lesion length (mm)Target artery (%)ACC/AHA class (%)Multivessel disease (%)Previous MI (%)AP (%)
ACC, American College of Cardiology; ACS, acute coronary syndrome; AHA, American Heart Association; AP, angina pectoris; LAD, left anterior descending coronary artery; LCX, left circumflex coronary artery; MI, myocardial infarction; PCI, percutaneous coronary intervention; RCA, right coronary artery; RVD, reference vessel diameter.
Sirolimus trials
SIRIUS (2003)4Stable or unstable AP, signs of myocardial ischaemia2.8014.40443125836332342315853
E-SIRIUS (2003)1Stable or unstable AP, silent ischaemia2.5515.00562123NANANANA3642NA33
C-SIRIUS (2004)3Stable or unstable AP, silent ischaemia2.6313.60364123NANA5940421251
DIABETES (2005)30Symptoms or objective evidence of ischaemia2.3415.00413722NANA806537NANA
RAVEL (2002)2Stable or unstable AP, silent ischaemia2.629.58502723637570NA363950
SES-SMART (2004)8ACS, stable AP, silent myocardial ischaemia as shown by exercise stress test2.2011.84281630254724465NANANA
Paclitaxel trials
TAXUS I (2003)5Stable or unstable AP or silent ischaemia2.9711.304030302341360NA28NANA
TAXUS II (2003)6, 32, 33Stable or unstable AP or silent ischaemia2.7510.48453619NANANANANA406034
TAXUS IV (2004)7, 29Stable or unstable angina or provokable ischaemia2.7513.40413128NANANANANA30NA34
TAXUS VI (2005)31Stable or unstable AP or silent ischaemia2.7820.62NANA2856NANANANA